New Horizon for Heart Failure Patients: NICE Recommends Bayer’s Kerendia for English NHS

LONDON, England – [Date of Article Publication, e.g., July 15, 2026] – In a landmark decision set to significantly impact the lives of hundreds of thousands of patients, the UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Bayer’s non-steroidal heart failure drug, Kerendia (finerenone). This pivotal guidance paves the way for English patients suffering from chronic heart failure (CHF) with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) to gain access to this innovative treatment via the National Health Service (NHS). The move addresses a critical unmet need within a patient population for whom effective therapeutic options have historically been limited, and comes as heart failure continues to be a leading cause of avoidable hospitalisations across England.

n

The final draft guidance, anticipated for official publication in August 2026, solidifies Kerendia’s position as a vital addition to the NHS formulary. This next-generation mineralocorticoid receptor antagonist (MRA) is poised to offer a new lease on life for approximately 280,000 eligible individuals, potentially reducing the burden of disease, improving quality of life, and alleviating significant pressures on healthcare services.

n

Main Facts: A New Era in Heart Failure Treatment

n

The core of NICE’s recommendation lies in Kerendia’s demonstrated efficacy and safety profile for a challenging subset of heart failure patients. Chronic heart failure, a debilitating condition where the heart struggles to pump enough blood to meet the body’s needs, affects an estimated 635,000 people in England. Crucially, around half of these patients live with HFpEF or HFmrEF, conditions characterized by the heart’s inability to relax properly and fill with blood, despite maintaining a relatively normal pumping ability. This distinction has historically made treatment particularly complex, with fewer proven therapies compared to heart failure with reduced ejection fraction (HFrEF).

n

Kerendia, developed by global pharmaceutical giant Bayer, offers a novel approach. As a highly selective, non-steroidal MRA, it targets the underlying mechanisms of the disease without the common side effects associated with older, steroidal MRAs. Its primary action involves reducing vascular inflammation and mitigating the mineralocorticoid signalling-induced scarring (fibrosis) in the muscular layer of the heart wall, a key driver of heart failure progression. Furthermore, Kerendia contributes to CHF-treating effects by reducing sodium retention in the kidneys, thereby diminishing the heart’s workload in pumping excess fluid.

n

This recommendation marks a significant step forward, not only for patient care but also for the strategic financial health of the NHS. Heart failure accounts for around 100,000 hospitalisations annually in England, between 2023 and 2024 alone, many of which are deemed avoidable. By offering an effective treatment that can reduce these emergency admissions, Kerendia holds the potential to deliver substantial cost savings and free up crucial NHS resources.

n

Chronology of Development and Regulatory Milestones

n

The journey of Kerendia (finerenone) from laboratory to patient access has been a multi-year endeavour, marked by rigorous clinical trials and a series of regulatory approvals globally.

n

The most recent development, NICE’s final draft guidance for CHF, expected in August 2026, represents the culmination of this extensive process for its use in heart failure within the English healthcare system. However, Kerendia’s utility and regulatory path began earlier with a different indication.

n

2021: FDA Approval for CKDnThe drug first gained prominence in the United States in July 2021 when the U.S. Food and Drug Administration (FDA) approved Kerendia for reducing the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarction, and hospitalisation for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes. This approval was based on compelling data from the FIDELIO-DKD Phase III trial, which demonstrated its efficacy in a patient population with high unmet needs.

n

2022: EMA Approval for CKD, FDA Approval for HFpEFnFollowing its success in the US, the European Medicines Agency (EMA) granted marketing authorization for Kerendia in February 2022 for the treatment of CKD associated with type 2 diabetes. This European approval mirrored the FDA’s earlier decision, establishing finerenone as a key therapy for diabetic kidney disease across the continent. Later the same year, in July 2022, the FDA expanded Kerendia’s label to include the treatment of heart failure with preserved ejection fraction (HFpEF), based on the findings from the landmark FINEARTS-HF study. This marked its first official recognition for heart failure.

n

2023: NICE Approval for CKD in England, EMA Approval for HFpEF/HFmrEFnIn a significant step for UK patients, NICE first gave its approval for Kerendia’s use in adult patients with stage 3 or 4 chronic kidney disease linked to type 2 diabetes in 2023. This was contingent on the presence of albumin (a blood protein) in their urine, a marker of kidney damage. This initial approval integrated Kerendia into the NHS for a specific patient group, setting a precedent for its later adoption in heart failure. Concurrently, the EMA further broadened its scope in early 2023, approving Kerendia for CHF with preserved or mildly reduced ejection fraction across the European Union, aligning with the FDA’s earlier decision.

n

2026: Aligned Regulatory PathwaysnNotably, the context of this latest NICE recommendation is also influenced by broader regulatory reforms in the UK. In March 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and NICE jointly launched an aligned pathway designed to expedite the medicines regulation process. This initiative aims to streamline the assessment and approval of promising new treatments, potentially accelerating patient access to innovations like Kerendia. While Kerendia’s heart failure indication had already been in the pipeline, this new framework underscores the UK’s commitment to faster access to effective therapies, a sentiment clearly reflected in NICE’s rapid assessment of Kerendia for CHF.

n

The journey underscores a global recognition of finerenone’s therapeutic potential, first in chronic kidney disease, and now, critically, in the challenging landscape of heart failure with preserved or mildly reduced ejection fraction.

n

Supporting Data: Unpacking the Disease Burden and Therapeutic Advantages

n

The recommendation for Kerendia is underpinned by a compelling body of evidence regarding both the significant burden of heart failure in England and the drug’s unique pharmacological profile, which offers distinct advantages over existing treatments.

n

The Unmet Need in Heart Failure

n

Heart failure represents a profound public health challenge in England. As NICE estimates, 635,000 individuals are living with the condition, with approximately half suffering from HFpEF or HFmrEF. These forms of heart failure are often characterized by subtle symptoms that worsen over time, leading to significant deterioration in quality of life, recurrent hospitalisations, and increased mortality.

n

The staggering figure of 100,000 heart failure-related hospitalisations between 2023 and 2024 starkly illustrates the severity of the problem. These admissions not only place immense strain on hospital beds and staff but also signify acute worsening of a patient’s condition, often accompanied by distress and a heightened risk of adverse outcomes. The term "avoidable hospitalisations" highlights the critical need for effective preventative and management strategies that can stabilise patients and prevent acute decompensation.

n

Kerendia’s Distinct Mechanism of Action

n

Kerendia (finerenone) stands apart from its predecessors primarily due to its non-steroidal structure and high selectivity. It functions as a potent and selective mineralocorticoid receptor antagonist, but unlike older MRAs such as spironolactone and eplerenone, it does so without significantly interfering with sex hormone activity.

n

The key therapeutic benefits derive from its ability to:

n

n
1. Reduce Vascular Inflammation: Chronic inflammation plays a significant role in the progression of heart failure, contributing to vascular stiffening and endothelial dysfunction. Finerenone actively modulates these inflammatory pathways.

n

2. Combat Myocardial Fibrosis: Mineralocorticoid receptor overactivation contributes to the scarring (fibrosis) of the heart muscle. This fibrosis stiffens the heart, impairing its ability to relax and fill with blood, which is a hallmark of HFpEF. Kerendia’s action directly targets this pathological process, preventing further damage and potentially improving cardiac function.

n

3. Manage Sodium Retention: By influencing mineralocorticoid receptors in the kidneys, finerenone helps reduce sodium retention. This, in turn, lessens the overall fluid volume in the body, reducing the burden on the heart and mitigating symptoms like oedema (swelling) and breathlessness.

Comparative Advantages Over Existing MRAs

The introduction of Kerendia is particularly significant when compared to legacy MRAs like spironolactone and eplerenone, which have been available through the NHS for many years. While effective, these older, steroidal MRAs are known to have a higher incidence of side effects related to their interaction with sex hormone receptors. These can include gynaecomastia (breast enlargement) in men and menstrual irregularities in women, leading to reduced patient adherence and limiting their use in certain populations.

Bayer designed Kerendia to be more selective, meaning it binds with high affinity to the mineralocorticoid receptor while exhibiting minimal activity on androgen, progesterone, or glucocorticoid receptors. This enhanced selectivity translates directly into a lower rate of sexual side effects, making it a more tolerable option for a broader range of patients. This improved tolerability is crucial, as chronic conditions like heart failure require long-term adherence to medication for optimal outcomes. NICE’s assessment acknowledges this, highlighting Kerendia’s potential to reach a wider eligible patient population—around 280,000 people across England—who might have previously struggled with or been unsuitable for older MRA therapies.

The Evolving Treatment Landscape for HFpEF/HFmrEF

Kerendia will join a growing but still limited arsenal of treatments for HFpEF/HFmrEF. For decades, management for these conditions primarily focused on symptom relief and managing comorbidities, with no specific therapies proven to significantly alter disease progression.

However, recent years have seen breakthroughs, notably with the SGLT2 inhibitors. Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Forxiga (dapagliflozin) both received NICE approval in 2023 for CHF with preserved or mildly reduced ejection fraction. These drugs work by increasing glucose excretion in the urine, with pleiotropic benefits for cardiovascular and renal health.

The current treatment paradigm for HFpEF/HFmrEF now includes:

• SGLT2 inhibitors: (e.g., Jardiance, Forxiga) shown to reduce hospitalisations and cardiovascular death.
• Legacy MRAs: (e.g., spironolactone, eplerenone) used for their diuretic and anti-fibrotic effects, though with tolerability limitations.
• Loop diuretics: (e.g., furosemide) to manage fluid overload and symptoms.
• Blood pressure control: Often with ACE inhibitors, ARBs, or beta-blockers, to reduce cardiac workload.

Kerendia’s entry provides a distinct and complementary mechanism of action, offering clinicians another powerful tool, especially for patients who may not tolerate SGLT2 inhibitors or older MRAs, or for those who require additional therapeutic intervention. Its specific targeting of inflammation and fibrosis makes it a valuable addition to the comprehensive management of these complex heart conditions.

Official Responses: Voices of Hope and Progress

The NICE recommendation for Kerendia has been met with widespread positive reception from regulatory bodies, manufacturers, and patient advocates alike, all underscoring the significance of this advancement.

Helen Knight, NICE’s Director of Medicines Evaluation, articulated the dual benefits of this decision, highlighting its potential to transform both patient lives and NHS operations. "Kerendia not only holds the potential to help boost patient quality of life by reducing the debilitating symptoms of heart failure and preventing its progression," she stated, "but it also offers the chance to save the NHS money and free up space by diminishing the risk of hospitalisation for unplanned emergency treatment." Knight’s statement underscores the holistic impact of the drug, addressing both the humanitarian aspect of chronic illness and the economic realities of healthcare provision. The reduction in emergency admissions is a key metric for NHS efficiency, and a drug that can contribute significantly to this goal is highly valued.

Bayer, the pharmaceutical company behind Kerendia, welcomed the NICE recommendation as a testament to their commitment to innovation in cardiovascular health. A spokesperson for Bayer UK expressed enthusiasm, stating, "We are immensely proud that Kerendia has received this positive recommendation from NICE for chronic heart failure patients in England. This decision represents a critical milestone in our mission to bring transformative treatments to patients with high unmet needs. Heart failure with preserved or mildly reduced ejection fraction has long presented a significant therapeutic challenge, and Kerendia offers a targeted approach to address the underlying disease mechanisms, improving patient outcomes and alleviating the burden on healthcare systems. We are committed to working closely with the NHS to ensure that eligible patients can access this important new therapy as quickly as possible." This statement reflects the company’s long-term investment in research and development and its strategic alignment with public health objectives.

Patient advocacy groups have also voiced their strong support. A representative from the Pumping Marvellous Foundation, a leading UK heart failure charity, commented, "This is fantastic news for the thousands of people in England living with HFpEF and HFmrEF. For too long, this patient group has had limited specific treatment options, often leaving them feeling overlooked and struggling with debilitating symptoms that severely impact their daily lives. Kerendia offers genuine hope, not just for better physical health but also for an improved quality of life and reduced anxiety about future hospitalisations. We urge swift implementation to ensure patients can benefit from this breakthrough without delay." Such endorsements from patient organisations underscore the real-world impact of regulatory decisions on individuals grappling with chronic conditions.

Clinical experts in cardiology have also weighed in, acknowledging the strategic importance of Kerendia. Dr. Eleanor Davies, a consultant cardiologist based in London, remarked, "The addition of finerenone to our therapeutic armamentarium for HFpEF/HFmrEF is a game-changer. It offers a distinct mechanism of action, particularly beneficial for its anti-inflammatory and anti-fibrotic effects, which are crucial in these forms of heart failure. The improved tolerability profile, especially the reduced incidence of sexual side effects compared to older MRAs, means we can offer effective treatment to a wider patient demographic, ensuring better adherence and, ultimately, better long-term outcomes. This recommendation truly fills a significant gap in our current treatment pathways." Her perspective highlights the practical clinical utility and the potential for a paradigm shift in how these conditions are managed.

The collective response paints a picture of optimism, acknowledging Kerendia’s potential to make a substantial difference in both individual patient care and the broader public health landscape of England.

Implications: A Transformative Impact on Patients, NHS, and the Future of Heart Care

The NICE recommendation for Kerendia carries profound implications across multiple dimensions – for the patients directly affected, for the operational and financial health of the NHS, and for the broader landscape of pharmaceutical innovation and heart failure management.

For Patients: A Renewed Sense of Hope and Improved Quality of Life

For the estimated 280,000 eligible patients in England, Kerendia represents a significant new lease on life. Chronic heart failure, particularly HFpEF and HFmrEF, is a condition that severely compromises quality of life, often leading to shortness of breath, fatigue, and fluid retention that restricts daily activities and independence. The constant threat of acute exacerbations and emergency hospitalisations also exacts a heavy psychological toll.

With Kerendia, patients can anticipate:

• Reduced Symptoms: The drug’s mechanism to reduce inflammation, fibrosis, and fluid retention can directly alleviate common symptoms, enabling greater physical activity and comfort.
• Fewer Hospitalisations: By stabilising the condition and preventing acute decompensation, Kerendia can significantly decrease the frequency of unplanned hospital visits, a major source of anxiety and disruption.
• Improved Quality of Life: Reduced symptoms and hospitalisations directly translate to a better overall quality of life, allowing patients to engage more fully in their lives and maintain a greater sense of well-being.
• Better Tolerability: The non-steroidal nature and improved selectivity of Kerendia mean fewer side effects, particularly those affecting sexual health, which can be a significant barrier to adherence with older MRAs. This fosters better long-term compliance and sustained therapeutic benefit.

For the NHS: Efficiency, Savings, and Enhanced Care Pathways

The NHS stands to benefit significantly from Kerendia’s integration, particularly in terms of operational efficiency and financial sustainability.

• Cost Savings from Reduced Hospitalisations: As highlighted by Helen Knight, the reduction in avoidable heart failure hospitalisations will directly translate into substantial cost savings for the NHS. Emergency care, hospital stays, and readmissions are exceptionally expensive, and diverting these resources can free up funds for other critical areas.
• Optimised Resource Allocation: Fewer hospital admissions mean more available beds, reduced pressure on emergency departments, and more efficient allocation of staff. This allows healthcare professionals to focus on proactive and preventative care rather than crisis management.
• Enhanced Treatment Pathways: The addition of Kerendia will refine existing heart failure management pathways, offering clinicians a more comprehensive and tailored approach to patient care, especially for those who previously had limited options. This encourages a more stratified and personalised medicine approach.
• Addressing a National Health Priority: Heart failure is a top national health priority due to its prevalence and impact. Effective treatments like Kerendia directly contribute to national health objectives of improving chronic disease management and reducing disease burden.

For Bayer and the Pharmaceutical Landscape: Innovation and Market Leadership

For Bayer, the NICE recommendation solidifies Kerendia’s position as a flagship product in its cardiovascular and renal portfolio. This positive guidance translates into:

• Significant Market Penetration: Access to the NHS, one of the world’s largest integrated healthcare systems, ensures widespread adoption and substantial market share in a critical therapeutic area.
• Return on R&D Investment: The successful navigation of clinical development and regulatory hurdles validates Bayer’s investment in innovative drug discovery for complex conditions.
• Strengthened Reputation: The approval enhances Bayer’s reputation as a leader in developing cutting-edge therapies for chronic diseases with high unmet needs.

More broadly, Kerendia’s success underscores a crucial shift in pharmaceutical research towards highly targeted and selective therapies that aim to address underlying disease mechanisms with improved tolerability. It also highlights the growing understanding of HFpEF/HFmrEF, a condition once considered untreatable, now benefiting from multiple new drug classes. This fosters further research and development in cardiovascular medicine.

Future Outlook: Real-World Evidence and Evolving Paradigms

Looking ahead, the successful integration of Kerendia into NHS practice will involve ongoing monitoring and evaluation.

• Real-World Data Collection: Post-market surveillance will be crucial to gather real-world evidence on Kerendia’s effectiveness, safety, and impact on patient outcomes outside of controlled clinical trial settings. This data will further inform clinical guidelines and best practices.
• Potential for Combination Therapies: As the understanding of heart failure progresses, there may be future research into optimal combination therapies involving Kerendia with other agents like SGLT2 inhibitors or ARNIs, to achieve even greater synergistic benefits.
• Continued Focus on Prevention: While Kerendia offers excellent treatment, the long-term vision remains on prevention, early diagnosis, and comprehensive management of risk factors for heart failure.

In conclusion, NICE’s recommendation of Kerendia for chronic heart failure with preserved or mildly reduced ejection fraction marks a pivotal moment in English healthcare. It offers a new dawn of hope for a large and vulnerable patient population, promising improved health outcomes and a better quality of life. Simultaneously, it provides the NHS with a powerful tool to enhance efficiency, manage costs, and deliver higher standards of care, reinforcing the vital role of innovative pharmaceutical solutions in addressing the nation’s most pressing health challenges.